NDLI: Primary effusion lymphoma: current perspectives

Please wait, while we are loading the content...

Primary effusion lymphoma: current perspectives

Content Provider	Scilit
Author	Narkhede, Mayur Arora, Shagun Ujjani, Chaitra
Copyright Year	2018
Description	Journal: OncoTargets and therapy Primary effusion lymphoma: current perspectives Mayur Narkhede,1 Shagun Arora,2 Chaitra Ujjani1 1Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA; 2Division of Hematology and Oncology, University of California, San Francisco, CA, USA Primary effusion lymphoma (PEL) is a rare and aggressive disease, affecting a unique population of patients who are often elderly or immunocompromised. PEL is associated with human herpesvirus type-8 infection and most commonly presents as malignant effusions of the body cavities. Patients diagnosed with PEL often have a compromised immune system from secondary conditions such as HIV. Chemotherapy has traditionally been the cornerstone of treatment for patients with a good performance status and no significant comorbidities. However, an optimal regimen does not exist. Most patients with PEL experience a relapse after frontline therapy within 6–8 months and subsequently require further treatment. In recent years, our understanding of the molecular drivers and environmental factors affecting the pathogenesis of PEL has expanded. This review will discuss the pathogenesis of PEL and various management approaches available in the frontline and relapsed setting as well as targeted agents that have shown promise in this disease. Keywords: HIV-associated lymphomas, primary effusion lymphoma, HHV8-associated lymphomas
Related Links	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029609/pdf https://www.dovepress.com/getfile.php?fileID=42868
Ending Page	3754
Page Count	8
Starting Page	3747
ISSN	11786930
DOI	10.2147/ott.s167392
Journal	OncoTargets and therapy
Volume Number	ume 11
Language	English
Publisher	Informa UK Limited
Publisher Date	2018-06-01
Access Restriction	Open
Subject Keyword	Journal: OncoTargets and therapy Hhv8-associated Lymphomas Hiv-associated Lymphomas Primary Effusion Lymphoma
Content Type	Text
Subject	Pharmacology (medical) Oncology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in